Board of Pharmacy Specialties Portfolio Requirements for Added Qualifications in Infectious Diseases Pharmacotherapy

Similar documents
Antimicrobial EUHM Learning Activities:

OPINION PAPER. (Pre-publication Draft)

PGY1 Course Description

ROTATION DESCRIPTION FORM PGY1

Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess.

CLINICAL PRIVILEGE WHITE PAPER

Department of Pharmacy Services PGY1 Residency Program. Residency Manual

PGY-2 PEDIATRIC PHARMACY RESIDENCY MEDICAL UNIVERSITY OF SOUTH CAROLINA

Petitioner's Guide for Recognition of a Pharmacy Practice Specialty

Improving Access in Infusion Therapy

UNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM

Course Descriptions for PharmD Classes of 2021 and Beyond updated November 2017

Northwest Utilization Management Policy & Procedure: UR 13a Title: Formulary Exception Process and Excluded Drug Review

Acute Care Cardiology Learning Description at Emory University Hospital Midtown (EUHM)

ADAPT Course Prospectus. Elevate your practice to the next level of patient care.

Colorado Board of Pharmacy Rules pertaining to Collaborative Practice Agreements

PGY 1 Pharmacy Residency Cardiology Experience Description Truman Medical Center Hospital Hill

Infectious EUH Learning Activities:

ROTATION DESCRIPTION

PRE-SURVEY QUESTIONNAIRE AND SELF-ASSESSMENT CHECKLIST FOR THE ACCREDITATION OF A POSTGRADUATE YEAR ONE (PGY1) PHARMACY RESIDENCY PROGRAM

Practice Standards, Training, and Professional Development

ACPE Standards for Continuing Pharmacy Education. Standard 1: Mission and Goals of CPE. Standard 1: Goal and Mission of the.

UNMC COLLEGE OF PHARMACY ADVANCED PHARMACY PRACTICE EXPERIENCE SYLLABUS (Revised November 2014)

Incorporating the Pharmacists Patient Care Process into Practice

Educational Outcomes, Goals, and Objectives for Postgraduate Year Two (PGY2) Pharmacy Residencies in Internal Medicine

Mission: To extend the presence and healing ministry of Christ in all we do.

RACMA GUIDE TO PRACTICAL CREDENTIALING AND SCOPE OF CLINICAL PRACTICE PROCESSES

Block Title: Patient Care Experience Block #: PHRM 701, 702, 703, 704 and PHRM 705, 706, and 707 (if patient care)

2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program

Northwest Utilization Management Policy & Procedure: UR 13a Title: Formulary Exception Process and Excluded Drug Review

Experiential Education

How to Add an Annual Facility Survey

Core Elements for Antibiotic Stewardship in Nursing Homes

Neurology Clinic - Ambulatory Care I & II

The implementation of a clinical training program for staff pharmacists

Canadian Pharmacy Residency Board

CHOC Children s Department of Pharmacy Services Post Graduate Year Two Residency Program Residency Handbook

American Journal of Pharmaceutical Education 2003; 67 (3) Article 88.

PGY1: Pediatric Infectious Diseases Riley Hospital for Children Indiana University Health

ASHP Accredited PGY1 & PGY2 Residency with Master s Degree in Health-System Pharmacy Administration

PGY2 AMBULATORY CARE PHARMACY RESIDENCY MEDICAL UNIVERSITY OF SOUTH CAROLINA

UNMC COLLEGE OF PHARMACY ADVANCED PHARMACY PRACTICE EXPERIENCE (APPE) SYLLABUS (Revised February 2013, Approved April 2013)

RULE RESPONSIBILITIES OF A PHYSICIAN WHO ENGAGES IN DRUG THERAPY MANAGEMENT WITH A COLORADO LICENSED PHARMACIST

COURSE TITLE: Adult Medicine: Phar 9981

PGY1 Infectious Disease Longitudinal Rotation

Hospital Crosswalk. Medicare Hospital Requirements to 2012 Joint Commission Hospital Standards & EPs

Results from Antimicrobial Stewardship (AMS) Program Implementation

ROTATION DESCRIPTION - PGY1 Adult Internal Medicine

Chapter 1. Scope of Clinical Pharmacy. M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Ambulatory Care Advanced Pharmacy Practice Experience Course Title: PHAR 9981

Postgraduate Year One (PGY1) Pharmacy Residency Program

Leadership Engagement in Antimicrobial Stewardship

Stellar Hospital PGY-1 Pharmacy Residency

DEFINING CANADIAN CERTIFICATION FOR ONCOLOGY PHARMACISTS

Structured Practical Experiential Program

ARTICLE IV. MEDICAL STAFF CATEGORIES. The Active Staff shall consist of practitioners each of whom:

University of Virginia Health System Department of Pharmacy Services PGY2 Drug Information Residency Residency Purpose Statement

2018 BPS SEED GRANT APPLICATION FOR PGY-2 RESEARCH PROJECTS

UNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2017 October 1 st, 2016

Specialist Member Call for Nominations Board of Pharmacy Specialties Specialty Council on Pharmacotherapy. Nominee Information Winter 2018

Application summary. Lead applicant. Application title. What stage of Fellowship are you applying for? Proposed duration of funding (months)

CHAPTER SIX STANDARDS FOR NURSING EDUCATION PROGRAMS

Antithrombotic Traineeship

PHARMACY (PHAR) PHAR 534. Foundations III. 1.5 Hour.

Learning Experiences Descriptions

Updates in Therapeutics 2015: Critical Care Pharmacy Preparatory Review Course

SECTION PROPOSAL FOR EDUCATION ACTIVITY:

PGY1 Pharmacy Residency Program Overview

College of Pharmacy. Pharmacy Practice and Science

Policy on continuing professional development activities

Portfolio: Expected Outcomes Student Survey

Canadian Pharmacy Residency Board. Accreditation Standards for Pharmacy (Year 1) Residencies

ELECTIVE COMPETENCY AREAS, GOALS, AND OBJECTIVES FOR POSTGRADUATE YEAR ONE (PGY1) PHARMACY RESIDENCIES

Integrating the LLM / JCPP-PPCP Seena Haines, PharmD, BCACP, FASHP, FAPhA, BC-ADM, CDE Jenny A. Van Amburgh, PharmD, RPh, FAPhA, BCACP, CDE

COMPETENCY BASED PROFESSIONAL PRACTICE STANDARDS

DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES

Advanced Pain Management and Palliative Care Application Policies and Guidelines

Medication Control and Distribution. Minor/technical revision of existing policy. ± Major revision of existing policy Reaffirmation of existing policy

PRE-SURVEY QUESTIONNAIRE AND SELF-ASSESSMENT CHECKLIST FOR ACCREDITATION OF: POSTGRADUATE YEAR ONE (PGY1) COMMUNITY PHARMACY RESIDENCY PROGRAMS

Understanding Antimicrobial Stewardship: Is Your Organization Ready? A S H LEIGH MOUSER, PHARM D, BCPS

Prior Assessed Learning (PAL) Application

PGY1 - Project Learning Experience Description

Anaesthesia Fellow. Position Description. Department : Department of Anaesthesia & Perioperative Medicine

September 16 th, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

ST. JAMES S HOSPITAL

Bethesda Hospital PGY1 Residency Program Learning Experiences

Medication Related Changes Phase 1&2

The Strategic Plan of the American College of Clinical Pharmacy 1

CONTINUING PHARMACY EDUCATION (CPE) Project Planning Form for Live and Enduring Activities

Standards of Practice for. Recreation Therapists. Therapeutic Recreation Assistants

Preceptor Development: Patient Care Process. Introduction

Decreasing Readmissions in Outpatient Parenteral AntImicrobial Therapy (DROP IT)

UC San Diego Policy & Procedure Manual

GOALS. I. Monitoring the quality of health care for safety, effectiveness and efficiency and seek opportunities for improvement

M.S. in Nursing 2006 NCA Progress Report #9

EVIDENCE-BASED REVIEW PROCESS FOR FORMULARY DRUG ADDITION

PAIN MANAGEMENT AND PALLIATIVE CARE TRAINEESHIP, LEVEL 3

FERRIS STATE UNIVERSITY COLLEGE OF PHARMACY APPROVED BY FACULTY AUGUST 20, 2014

SPECIALIZATION IN PHARMACY: THE QUEBEC EXPERIENCE

PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK

Transcription:

Effective 2016-2017 Application cycle Board of Pharmacy Specialties Portfolio Requirements for Added Qualifications in Infectious Diseases Pharmacotherapy Board Certified Pharmacotherapy Specialists (BCPS) seeking recognition of Added Qualifications in Infectious Diseases must submit one online application that contains sufficient information to justify this additional credential and clearly defines the distinction between the individual and other BCPS who do not qualify for this additional recognition. Portfolios are reviewed on an annual basis. Applications for Added Qualifications must be received by December 31 of each year for review the following January. The required elements of the portfolio are listed below. The portfolio must contain all required elements. If all required elements are NOT submitted, the application will be denied. Should the applicant need to provide clarification the document will be reviewed the following cycle upon resubmission by the applicant. 1. Letter from applicant requesting review of portfolio for purpose of granting Added Qualifications in Infectious Diseases Pharmacotherapy. 2. A completed online application including a detailed summary of each of the elements presented in Appendix A with examples and timeframes (where applicable) below each statement. A CV should not be submitted. Note: Experience associated with a training program, such as a residency or fellowship, should not be included; only those experiences and publications occurring as an independent practitioner will be considered as part of your application. Applicants must have at least 2 years experience after terminal training in order to be eligible for Added Qualifications. All applications must be submitted online by December 31. 1

APPENDIX A Process for Reviewing and Scoring Portfolios for Infectious Diseases Pharmacotherapy The Specialty Council will ap a Portfolio Review Committee, whose members will individually evaluate the submitted portfolios based on the scoring system described below. The Portfolio Review Committee will report its findings to the Specialty Council, which in turn recommends to BPS those individuals whose portfolios meet the designated evaluative standards and thus should be granted Added Qualifications. An engraved certificate will be mailed to each BCPS who has been granted Added Qualifications. Those applicants who do not achieve the minimum score will receive an email indicating the section(s) where the necessary minimum score was not attained. These applicants will be invited to reapply in a subsequent application cycle if they can strengthen their portfolio. The scoring system described below was developed by a committee of the Society of Infectious Diseases Pharmacists (SIDP) and the BPS Specialty Council on Pharmacotherapy, and approved by BPS. Each item identified below will be evaluated based on either a NO response or a YES response. For all NO responses, 0 will be awarded. For all YES responses, all the shown for that item will be awarded. In other words, either all or no will be granted for each item. In order for Added Qualifications to be conferred, the minimum score for each section (as indicated) must be achieved, as well as at least 15 total (50% of the possible maximum score). The necessary total score of at least 15 for conferral of Added Qualifications documents at least minimal activity in infectious diseases patient care, research and/or education, and demonstrates predominant activity in at least one of these areas. Note: Experience associated with a training program, such as a residency or fellowship, should NOT be included; only those experiences and publications occurring as an independent practitioner over the past 7 years will be considered as part of this application process. A. The infectious diseases pharmacotherapist designs, implements, monitors, evaluates, and modifies patient pharmacotherapy to ensure effective, safe, and economical therapy in patients with infectious diseases. 1. Is a member of an interdisciplinary infectious diseases team contributing regularly to the care of patients with infectious diseases, documenting their services and interventions, including verbal and written consultations for individual patient care. 2. Monitors patients, assesses therapy, and intervenes to optimize pharmacotherapy of infectious diseases. 3. Is consistently involved in formal education of patients and/or patient groups regarding infectious diseases pharmacotherapy OR 2

4. Documents PRIOR professional experience (within the last 7 years) in the management of patients with infectious diseases as outlined in at least two of 1, 2, and/or 3 above. (Minimum Section Score: 0 ) (Maximum Section Score: 6 ) B. The infectious diseases pharmacotherapist retrieves, analyzes, and interprets scientific literature to enhance the provision of patient- and population-specific infectious diseases information and clinical care. 1. Is a member of an Antibiotic Committee, Pharmacy and Therapeutics Committee, Infection Control Committee, or Practice Guideline Development Committee (or equivalents) 2. Manages or participates in antibiotic use programs, implementation of clinical pathways, or specific infection control activities at the local institutional level. 3. Develops written peer-reviewed infectious diseases drug information monographs, review articles, or summaries for use by other health care professionals. (minimum of 3) (Minimum Section Score: 0 )* (Maximum Section Score: 6 ) C. The infectious diseases pharmacotherapist regularly participates in the generation of new knowledge relevant to the practice of infectious diseases pharmacotherapy. 1. Designs or collaborates on investigator-initiated research in infectious diseases pharmacotherapy. 2. Presents results of infectious disease research at national or international scientific meetings and/or publishes peer-reviewed reports of original infectious diseases research. A list of presentation, publications, and dates should be included (minimum 12 presentations or publications). 3. Serves as reviewer or editor for scientific/profession publications in infectious diseases. (include journal name(s) and years) (Minimum Section Score: 0 )* (Maximum Section Score: 5 ) *A minimum score of 4 is required in either section A or C AND ** A minimum score of 2 is required in either section B or C 3

D. The infectious diseases pharmacotherapist educates health care professionals, students, patients, and the public regarding rational infectious diseases pharmacotherapy. 1. Serves as a preceptor in infectious diseases specialty training program, ie., infectious diseases specialty residency and/or infectious diseases fellowship that may be for pharmacists or other health care providers. (mutually exclusive from D3 below) 2. Provides educational presentations/in-service lectures on infectious diseases topics on a regular basis to health care professionals, and/or those in training. A list of the titles of topics presented and the dates should be included. 3. Regularly precepts infectious diseases clerkship experiences for health care professionals in training. (This is mutually exclusive from D1 above, thus excludes precepting for infectious diseases specialty residency or fellowship training.) 4. Develops/provides unique programs for patient and/or public education concerning infectious diseases topics. A list of projects and dates should be included. 5. Organizes or offers special training or professional development programs in infectious diseases pharmacotherapy (i.e. certificate programs, short courses, laboratory sabbaticals). Describe involvement with program, including your role, frequency and duration of participation. A list of projects and dates should be included. (Minimum Section Score: 4 ) (Maximum Section Score: 10 ) E. Other Information Relevant to Portfolio Review 1. Holds membership in professional/scientific organizations for infectious diseases practitioners/researchers, beyond a subinterest group within a general organization. (e.g., ACCP PRN, ASHP SIG). Examples that meet this criteria include Infectious Diseases Society of America, Society of Infectious Disease Pharmacists, and American Society of Microbiology. List(s) and timeframe(s) here if applicable. 2. Has completed a post-graduate training program in infectious diseases pharmacotherapy (specialty residency, fellowship)or has practiced in area of infectious diseases pharmacotherapy for five years or more. 4

3. Has received an individual special award or recognition from a professional organization for demonstration of excellence in infectious disease pharmacotherapy clinical practice, education or research. (Minimum Section Score: 1 ) (Maximum Section Score: 3 ) 5